Mergers & Acquisitions
Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:
Leveraging our network of experienced Managing Directors, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and provide incisive and deeply informed advice about the merits of bids received.
We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.
Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.
Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s experience, expertise and discretion positions us well for special advisory assignments.
Greenhill’s network of international offices allow us to offer clients a seamless cross-border advisory service with a truly global perspective.
Advised InBev SA, the world's largest brewery, on the sale of German regional brewery Dinkelacker-Schwaben Bräu KG
Gallaher Group plc
Advised Gallaher Group plc, the world’s fifth largest tobacco company, on a recommended cash offer from Japan Tobacco Inc
Advised Gilde Buy Out Partners on the sale of CABB, a leading producer of monochloroacetic acid and related specialty intermediates, to AXA Private Equity
John Laing plc
Advised John Laing plc, the leading UK infrastructure investor and developer, on a recommended cash offer
Kos Pharmaceuticals, Inc.
Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories